Literature DB >> 12001278

Cytokines in severe respiratory syncytial virus bronchiolitis.

Kevin J Mobbs1, Rosalind L Smyth, Una O'Hea, Deborah Ashby, Paul Ritson, C Anthony Hart.   

Abstract

Bronchiolitis caused by respiratory syncytial virus (RSV) infection is an important cause of severe lung disease in infants, and increasing evidence suggests that it is immunologically mediated. Experiments in mice suggest that this may be due to differential T-cell activation producing either type 1 or type 2 cytokines. We investigated this hypothesis in man by studying 24 infants ventilated with severe RSV bronchiolitis and by measuring messenger RNA (mRNA) for interleukin-4 (IL-4) and interferon-gamma (IFN-gamma), by polymerase chain reaction, in nasopharyngeal aspirates (NPAs) and bronchoalveolar lavage (BAL) fluids. A semiquantitative assay was used to estimate concentrations of mRNA for these cytokines in comparison to mRNA of the constitutively expressed hypoxanthine guanine phosphoribosyl transferase gene. BAL from 18/24 infants showed polarization of cytokine production: 6 with only IFN-gamma mRNA, and 12 with only IL-4 mRNA. For the 6/24 infants in whom both IL-4 mRNA and IFN-gamma mRNA were detected in BAL fluid, each was present in low amounts, compared with those with mRNA for IL-4 or IFN-gamma alone. IL-4 and IFN-gamma mRNA were not detected in any of the NPAs.These findings provide the first direct evidence in infants that in RSV bronchiolitis there are divergent T-cell responses and suggest that more than one mechanism may be responsible for immune-mediated disease enhancement. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12001278     DOI: 10.1002/ppul.10101

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  16 in total

Review 1.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

Review 2.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

Review 3.  Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

Authors:  Peter L Collins; José A Melero
Journal:  Virus Res       Date:  2011-09-22       Impact factor: 3.303

Review 4.  The use of a neonatal mouse model to study respiratory syncytial virus infections.

Authors:  Stephania A Cormier; Dahui You; Srinivasa Honnegowda
Journal:  Expert Rev Anti Infect Ther       Date:  2010-12       Impact factor: 5.091

5.  Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice.

Authors:  Kate L Stokes; Michael H Chi; Kaori Sakamoto; Dawn C Newcomb; Michael G Currier; Matthew M Huckabee; Sujin Lee; Kasia Goleniewska; Carla Pretto; John V Williams; Anne Hotard; Taylor P Sherrill; R Stokes Peebles; Martin L Moore
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

Review 6.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

7.  Attenuation of live respiratory syncytial virus vaccines is associated with reductions in levels of nasal cytokines.

Authors:  Ruth A Karron; Bhagvanji Thumar; Elizabeth Schappell; Ursula J Buchholz; Peter L Collins
Journal:  J Infect Dis       Date:  2013-03-12       Impact factor: 5.226

8.  A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction.

Authors:  Martin L Moore; Michael H Chi; Cindy Luongo; Nicholas W Lukacs; Vasiliy V Polosukhin; Matthew M Huckabee; Dawn C Newcomb; Ursula J Buchholz; James E Crowe; Kasia Goleniewska; John V Williams; Peter L Collins; R Stokes Peebles
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

Review 9.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

Review 10.  Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics.

Authors:  H F Rosenberg; J B Domachowske
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.